Fact-checked by the Peptide Authority Editorial Board · Last reviewed: 2026-02-01
What Is Amylin? Benefits, Research & Safety
A pancreatic hormone co-secreted with insulin that regulates glucose and appetite, the basis for the diabetes drug pramlintide.
Also known as:
Islet Amyloid Polypeptide
IAPP
Pramlintide base
Educational Content Only: This page provides research-based information for educational purposes. Amylin is not an approved medicine. This is not medical advice. Always consult a qualified healthcare professional.
Quick Facts
Category
Fat Loss & Metabolic
Half-Life
Approximately 50 minutes (pramlintide)
UK Status
Pramlintide not widely available; not commonly used in UK practice.
EU Status
Pramlintide not approved in EU.
Overview
Amylin (also known as islet amyloid polypeptide or IAPP) is a 37-amino acid peptide hormone co-secreted with insulin from pancreatic beta cells in response to meals. It works alongside insulin to regulate blood glucose, with complementary but distinct mechanisms.
While insulin promotes glucose uptake and storage, amylin primarily regulates the rate of glucose entry into the bloodstream. It slows gastric emptying, suppresses glucagon secretion, and reduces appetite—all actions that help prevent postprandial glucose spikes.
In type 1 diabetes, amylin is absent (along with insulin); in type 2 diabetes, amylin secretion is impaired. This has led to development of amylin analogues as diabetes treatments.
Pramlintide (Symlin) is a synthetic analogue of amylin approved for diabetes treatment. It improves glycemic control and often produces modest weight loss due to appetite-suppressing effects.
Amylin's glucoregulatory and appetite effects have also generated interest in obesity treatment, leading to the development of cagrilintide and combination therapies (like cagrisema—cagrilintide plus semaglutide) currently in clinical development.
Discovery & History
Amylin was discovered in 1987 by Garth Cooper and colleagues, who isolated it from amyloid deposits in the pancreatic islets of patients with type 2 diabetes. The peptide was named for its tendency to form amyloid fibrils.
Initial research focused on the potential role of amylin aggregation in beta cell dysfunction and type 2 diabetes pathophysiology. The amyloid deposits seen in diabetic islets were composed primarily of aggregated IAPP.
Subsequent research revealed amylin's physiological functions as a hormone. Studies showed it complemented insulin by slowing gastric emptying, suppressing glucagon, and reducing food intake—all beneficial for glucose control.
Recognition that amylin was deficient in diabetes (absolute in type 1, relative in type 2) suggested therapeutic potential for amylin replacement. However, human amylin's tendency to aggregate complicated drug development.
Amylin Pharmaceuticals developed pramlintide, a modified amylin with three amino acid substitutions that prevent aggregation. Pramlintide (Symlin) received FDA approval in 2005 for use alongside insulin in type 1 and type 2 diabetes.
Current development focuses on longer-acting amylin analogues and combination therapies. Cagrilintide (a long-acting amylin analogue) combined with semaglutide (GLP-1 agonist) is in advanced development for obesity and shows particularly promising weight loss results.
Mechanism of Action
Amylin acts through specific receptors to complement insulin's actions:
**Amylin Receptors**
Amylin binds to calcitonin receptor complexed with RAMPs:
- Calcitonin receptor + RAMP1, 2, or 3 creates amylin receptors
- Widely distributed in brain, gut, and other tissues
- Activates cAMP signaling
**Gastric Emptying**
Slowing stomach emptying:
- Delays glucose entry into bloodstream
- Reduces postprandial glucose peaks
- Contributes to satiety
**Glucagon Suppression**
Inhibits inappropriate glucagon release:
- Glucagon normally raises blood glucose
- Amylin suppresses glucagon after meals
- Helps prevent postprandial hyperglycemia
**Appetite and Food Intake**
Central effects on appetite:
- Activates satiety centers in brainstem
- Reduces meal size
- May affect food reward
**Complementary to Insulin**
Works alongside insulin but differently:
- Insulin promotes glucose uptake
- Amylin regulates glucose rate of entry
- Together they optimise glucose control
[Molecular Structure Diagram Placeholder]
Researched Benefits
Based on preclinical and clinical research findings:
- 1Improved postprandial glucose control
- 2Reduced HbA1c in diabetes (pramlintide)
- 3Weight loss or prevention of weight gain
- 4Reduced glucagon spikes after meals
- 5Satiety enhancement and reduced food intake
- 6Potential for combination obesity therapy (with GLP-1 agonists)
Theoretical Dosing & Protocols
⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.
| Theoretical Dosage | Pramlintide: 15-120 mcg before meals (FDA approved doses) |
| Frequency | Before major meals (3 times daily) |
| Duration | Ongoing with diabetes management |
| Notes | Pramlintide is approved for use with insulin in type 1 and type 2 diabetes. Must be used alongside appropriate insulin dose reduction to avoid hypoglycemia. Not used as monotherapy. Medical supervision required. |
Administration Routes
Routes studied in research settings (educational only):
- Subcutaneous injection (pramlintide)
- Longer-acting analogues in development
| Half-Life | Stability |
|---|---|
| Approximately 50 minutes (pramlintide) | Pramlintide stable in solution per manufacturer specifications |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Nausea (common initially, usually improves)
- Headache
- Anorexia/reduced appetite
- Vomiting
- Injection site reactions
Rare Risks & Concerns
- Severe hypoglycemia (especially with inadequate insulin adjustment)
- Gastroparesis (avoid in patients with this condition)
Contraindications
- Gastroparesis
- Hypoglycemia unawareness
- Use requires appropriate insulin dose reduction
- Not for use in place of insulin
UK & EU Regulatory Context
🇬🇧 United Kingdom
Pramlintide not widely available; not commonly used in UK practice.
🇪🇺 European Union
Pramlintide not approved in EU.
Pramlintide is FDA-approved in the US for diabetes. Not approved in UK/EU. Cagrilintide (long-acting analogue) is in development; cagrisema (cagrilintide + semaglutide) is in Phase 3 for obesity with very promising results.
Clinical Studies Summary
Pramlintide in Diabetes
Clinical trials leading to FDA approval of pramlintide for diabetes management.
Diabetes journalsView on PubMed
Cagrilintide + Semaglutide (CagriSema)
Phase 2/3 trials showing exceptional weight loss with the amylin-GLP-1 combination.
Obesity and diabetes journalsView on PubMed
Looking for Amylin?
Source research-grade Amylin from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Related Peptides
Semaglutide
A GLP-1 receptor agonist approved for type 2 diabetes and obesity treatment, representing one of the most significant advances in weight management pharmacotherapy.
Learn moreLiraglutide
An earlier GLP-1 receptor agonist approved for diabetes and weight management, offering once-daily dosing with proven efficacy and safety.
Learn moreGLP-1
A naturally occurring gut hormone that regulates glucose metabolism and appetite, serving as the basis for major obesity and diabetes medications.
Learn moreGLP-1
A natural incretin hormone that regulates blood glucose and appetite, the basis for revolutionary diabetes and obesity medications.
Learn moreGhrelin
The 'hunger hormone' that stimulates appetite and growth hormone release, with important roles in metabolism and energy balance.
Learn moreSemaglutide
A once-weekly GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, representing a breakthrough in metabolic medicine with average weight loss of 15-17% in clinical trials.
Learn more